US equities
|
MU
$953.19
▼-3.62%
NVDA
$228.52
▲+0.97%
META
$762.50
▲+2.63%
AAPL
$341.27
▲+0.09%
MSFT
$543.45
▲+0.43%
SNDK
$1,482.33
▼-0.34%
AMD
$605.53
▲+1.90%
SPCX
$156.54
▼-4.21%
MU
$953.19
▼-3.62%
NVDA
$228.52
▲+0.97%
META
$762.50
▲+2.63%
AAPL
$341.27
▲+0.09%
MSFT
$543.45
▲+0.43%
SNDK
$1,482.33
▼-0.34%
AMD
$605.53
▲+1.90%
SPCX
$156.54
▼-4.21%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Churchill Capital Corp XI - Class A Ordinary Shares
(NQ:
CCXI
)
11.16
+0.38 (+3.53%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Churchill Capital Corp XI - Class A Ordinary Shares
< Previous
1
2
3
4
5
6
7
Next >
The First Pure-Play Humanoid Robot Stock Is About to Go Public. Here's What Investors Need to Know About Agility Robotics.
↗
Today 10:35 EDT
Like many other up-and-coming companies that are going public specifically because their business and their industry are clearly at a turning point, there's plenty of price-inflating hope here.
Via
The Motley Fool
Topics
Artificial Intelligence
Electric Vehicles
Grounded: SpaceX Stumbles as Grok Fails to Ignite
↗
July 09, 2026
SpaceX shares fell 8% after Nasdaq 100 inclusion as Grok's market share slipped, while Tesla dropped 7% despite a delivery beat, reflecting fading AI-driven valuation premiums.
Via
MarketBeat
Topics
Artificial Intelligence
Unusual volume stocks are being observed in Monday's session.
↗
July 06, 2026
Via
Chartmill
Unusual volume stocks in Thursday's session
↗
July 02, 2026
Via
Chartmill
ChemoCentryx: Q2 Earnings Insights
↗
August 09, 2022
ChemoCentryx (NASDAQ:CCXI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AI
↗
July 02, 2026
The CCXI-Agility Robotics SPAC merger will create the first U.S.-listed pure-play humanoid equity, valued at $2.5B, with clients including Amazon and a NVIDIA partnership.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
On Wednesday, there are stocks with unusual volume. Let's take a look.
↗
July 01, 2026
Via
Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
↗
June 30, 2026
Via
Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
↗
June 29, 2026
Via
Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
↗
June 26, 2026
Via
Chartmill
These stocks have an unusual volume in today's session
↗
June 25, 2026
Via
Chartmill
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share
↗
December 12, 2022
Via
Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
↗
November 23, 2022
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.
Via
Benzinga
Biotech Stocks Well-Positioned For The Fourth Quarter
↗
October 12, 2022
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.
Via
Talk Markets
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
↗
September 20, 2022
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022.
Via
Talk Markets
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year
↗
September 19, 2022
The biotech run off a June bottom is great — until you realize you could've netted more.
Via
Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
↗
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
7 Dow Stocks With Superior Fundamentals
↗
September 06, 2022
Robust Dow stocks offer attractive deals for patient investors amidst an unstable economic environment
Via
InvestorPlace
Healthcare Sector Still Looks Good But Lacks Momentum
↗
September 06, 2022
The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord...
Via
Talk Markets
ChemoCentryx's Return On Capital Employed Insights
↗
September 01, 2022
According to data from Benzinga Pro, during Q2, ChemoCentryx's (NASDAQ:CCXI) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million.
Via
Benzinga
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
↗
August 29, 2022
These names are benefitting from M&A, clinical data and promising regulatory actions.
Via
Investor's Business Daily
Whither Small Caps After Fed’s Tough Talk?
↗
August 29, 2022
For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and...
Via
Talk Markets
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
↗
August 23, 2022
The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie.
Via
Investor's Business Daily
Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation?
↗
August 15, 2022
The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring...
Via
Talk Markets
Why Jim Cramer Says This Financial Stock Is 'Terrific'
↗
August 12, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Charles Schwab Corporation (NYSE: SCHW) is "terrific."
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
↗
August 10, 2022
Via
Benzinga
Earnings Preview: ChemoCentryx
↗
August 08, 2022
ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx...
Via
Benzinga
Small Cap Biotechs Perk Up On Dealmaking
↗
August 06, 2022
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology.
Via
Talk Markets
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
↗
August 05, 2022
The Nasdaq and small caps rose while the S&P 500 is hitting resistance.
Via
Investor's Business Daily
Where ChemoCentryx Stands With Analysts
↗
August 05, 2022
Over the past 3 months, 4 analysts have published their opinion on ChemoCentryx (NASDAQ:CCXI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
